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Abstract:  
Respiratory syncytial virus (RSV) is a major cause of acute lower respiratory infection (ALRI) in young 
children aged <5 years. We aimed to identify the global inpatient and outpatient cost of management 
of RSV-ALRI in young children to assist health policy makers in making decisions related to resource 
allocation for interventions to reduce severe morbidity and mortality from RSV in this age group. We 
searched 3 electronic databases including Global Health, Medline and EMBASE for studies reporting 
cost data on RSV management in children under 60 months from 2000 to 2017. Unpublished data on 
the management cost of RSV episodes were collected through collaboration with an international 
working group (RSV GEN) and claim databases. We identified 41 studies reporting data from year 
1987 to 2017, mainly from Europe, North Americas and Australia, covering the management of a total 
of 365,828 RSV disease episodes. The average cost per episode was € 3,452 (95% CI:  3,265 - 
3,639) and € 299 (95% CI: 295 – 303) for inpatient and outpatient management without follow-up, 
and increased to € 8,591(95% CI: 8,489 – 8,692) and € 2,191 (95% CI: 2,190 – 2,192) respectively 
with follow-up to 2 years after the initial event. Known risk factors (early and late pre-term birth, 
congenital heart disease (CHD), chronic lung disease (CLD), intensive care unit admission and 
ventilator use) were associated with € 4,160 (95% CI: 3,237 – 5,082) increased cost of hospitalization. 
The global cost of inpatient and outpatient RSV ALRI management in young children in 2017 was 
estimated to be around € 4.82 billion (95%CI: 3.47 – 7.93), 65% of these in developing countries and 
55% of global costs accounted for by hospitalization. We have demonstrated that RSV imposed a 
substantial economic burden on health systems, governments and the society.  
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Respiratory syncytial virus (RSV) is recognized as the most frequent cause of acute lower respiratory 
infections (ALRI) in infants and children below 5 years of age. It is estimated that in 2015 about 3.2 
(95%CI: 2.7 – 3.8) million young children worldwide were hospitalized due to RSV-associated ALRI, 
while 59,600 (48,000 – 74,500) children younger than 5 years died in hospital from RSV globally[1]. 
The yearly seasonal outbreaks of RSV infections disproportionately affect young children, especially 
during their first year of life. A broad spectrum of disease presentations is observed, ranging from 
coughs and colds to severe bronchiolitis and pneumonia necessitating hospitalization. All forms of 
RSV disease cause a certain degree of burden on the healthcare system, financially as well as 
logistically.  
Currently, there are no licensed RSV vaccines available, but about 20 RSV vaccines and immune-
therapeutics are in clinical development[2]. The currently available prophylactic antibodies against 
RSV (polyclonal RSV-IVIG and monoclonal Palivizumab) are expensive, not widely available and only 
recommended for patients with a high risk of severe RSV disease[3]. This highlights the need for a 
global evaluation of management costs related to RSV disease, especially among those groups of 
patients who are not usually offered prophylaxis. Global cost evaluation would provide a better 
understanding of the disease impact on society and aid donors and health policy makers in setting 
priorities for development and introduction of new interventions. 
Therefore, we conducted a systematic review of the published literature and assembled unpublished 
data with the aim of identifying the overall costs related to management of RSV-ALRI episodes by 
country, classified by type of comorbidity and/or intervention.  
Materials and Methods 
Published literature: Search Strategy and Selection Criteria 
Following the PRISMA guidelines, Medline, EMBASE and Global Health (via the Ovid interface) were 
searched online to obtain maximum coverage of the published literature. General search headings 
identified were: Respiratory Syncytial Virus (RSV) and Economics. We focused on studies published 
between 1st Jan 2000 and 30th September 2017. Final search strategies were checked and approved 
by an independent librarian to ensure accuracy and validity of the search strategy. Three authors (S.Z., 
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B.F., L.Z.) independently screened the titles and abstracts of all records retrieved and checked the 
reference lists of eligible articles for further studies. We included studies published in English, Spanish, 
French and Chinese. Any disagreements were arbitrated by H.N. (Supplementary Table 1-3).  
We included all studies reporting RSV-related costs in children younger than 60 months. Treatment 
was provided to infected children according to local standard procedures. All studies documenting 
novel cost data were considered eligible. The inclusion and exclusion criteria are shown in 
Supplementary Table 4.  
Data Extraction 
We collected data, cost per episode, including direct medical, non-medical (transportation and food) 
and indirect costs (caregivers cost and productivity loss) and on length of stay (LOS) in hospitals. Unit 
costs for medicines and the utilization of resources were also documented if available. Three 
researchers (LZA, FB & SZ) extracted these data independently and final results were crosschecked.  
We designed a costing spreadsheet with detailed descriptions of case definitions and methods used 
for the data collection. Primary data collection was conducted using standardized templates and 
guidelines at each individual study site.  
Costs were first converted to the local currency, when needed, for the stated price year of the study, 
and inflated to their 2017 level using the country-specific gross domestic product (GDP) deflator index 
from the International Monetary Fund (IMF) World Economic Outlook database[4]. Then, all costs 
were converted to their equivalent price in 2017 $US based on the purchasing power parity of GDP 
(period average in 2017). Final results were then converted into 2017 € (1 US$ = €0.887397 )[5]. 
Industrialized and developing country designations followed UNICEF categories[6].  
Statistical Analysis  
The cost data were stratified by WHO region, follow-up and comorbidity status. Cost per episode, cost 
by component (direct medical, direct non–medical and indirect costs), length of stay and percentage 
of total costs per episode in each component were summarized. Relative estimates for risk group 
were obtained from each study.  
Based on data generated for each study, meta-analyses of cost per episode and LOS was quantified 
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using sample size weighted, random effect model of meta-analysis (metan command) in Stata V.12 
(StataCorp, College Station, Texas, USA). For each subgroup of RSV management, we summarized 
the data and reported a point estimate and 95% CI for the cost per episode and the respective LOS.  
Global costs of RSV management were modeled using recently published estimates for RSV 
episodes and RSV hospitalizations at global and regional levels in 2015[1]. We then applied these 
estimates to our unit cost estimates from each WHO region to generate global estimates for RSV-
related ALRI in children. We assumed that 90% and 63% of RSV positive cases in high-income and 
low and middle income countries respectively sought and received appropriate health-care [7]. Meta-
estimates for global costs were estimated using Monte Carlo simulation approach using @RISK, 
version 7.0 (Palisade Corp), as reported by Zimlichman et al.[8]. For each included study, we 
simulated a distribut with pooled results weighted by sample size. A point estimate of the cost per 
episode (with SD and 95%CI) in each study was reported based on a Monte Carlo simulation of 
100,000 sample draws.  
We used cost data from high-income countries for developed country settings. Due to limited RSV 
outpatient management cost data in low and middle-income countries, we used the cost ratio of 
pneumonia outpatient management cost between high income and low and middle-income 
countries[9], and calculated the costs of RSV management in low and middle-income countries 
reflecting costs for developing countries. 
Quality Assessment  
All papers were assessed using a modified Drummond Checklist for economic evaluation focusing on 
the methodological robustness and detail of reporting costs (Supplementary Table 5). Studies with 
quality score less than 5 (40% of total score) were considered to be of low quality and were excluded 
in the final analysis.  
Results 
Search Results 
The initial search strategy identified 3,581 references after excluding duplicates and a total of 38 
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published studies were considered eligible and included in the systematic review [10-47]. Three out 
of thirteen contacted sites provided additional unpublished data. A total of 41 studies were included 
in the final review (Figure 1).  
Study Characteristics 
A total of 365,828 RSV disease episodes were included in the cost analysis, including 338,542 
inpatient cases and 27,286 outpatient and emergency cases. The mean sample size of included 
studies was 8,923 (Range 12-94,252). A complete documentation of the characteristics of each study 
is summarized in Supplementary Table 6. 
Data covered 5 out of 6 WHO regions with no data from the African Region (Supplementary Figure 
1). Cost data were obtained from 14 countries, with studies from the United States representing the 
largest single group (n=18 or 44%). The majority of studies (32 studies) were cost-of-illness studies 
while the remaining 9 studies were cost-effectiveness studies, with 7 prospective and 34 retrospective 
studies. The perspective of costing was explicitly stated in 19 (46%) of the studies, with the most 
common perspective that of a third party payer (i.e. public or private health care insurers). Hospital 
chart, government and insurance databases were the most common sources for cost data.  
The majority of the included studies focused on children under 36 months of age (25 studies). 
Paediatric patients included general and/or high-risk patients (22 studies). RSV cases were identified 
by ICD 9 and 10 codes, direct immunofluorescence, indirect RSV antigen detection methods, RT-
PCR and viral culture.  
Cost reporting dates ranged from 1987 until 2016. Individual studies monitored costs over a mean 
period of 3.6 years (0.25 to 18 years). Ten studies (24%) were follow-up studies over a designated 
time period (1 month to 2 years) observing costs during and after initial RSV episodes.  
The average quality score was 8.9 points (SD 1.6, range 6,11) with a maximum possible score of 13 
(Supplementary Table 6). Most studies failed to report unit costs and the quantity of resources used, 
or discounting and sensitivity analyses. 
Cost per patient for RSV management  
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The global overall weighted mean cost per outpatient patient ranged from € 57 to  € 48,262) 
(Supplementary Figure 2). Costs for outpatient management (per disease episode) without follow-up 
(€299) were siginificantly lower compared to outpatient management (€ 2,191) with follow-up 
(Supplementary Table 1). For inpatient RSV management, mean cost per patient was € 4,712 (95% 
CI 4,568- 4,856, range € 92 to  € -165,602) (Figure 1). Studies with a follow-up period up to 2 years 
reported higher per patient costs on average (€ 8,591 vs € 3,452). RSV management costs were also 
higher in high income countries (€ 3,602) compared to middle income countries (€ 925). Cost data 
from low income countries were unavailable. 
At regional level, European Region (EUR) studies accounted for 40.3% of inpatient cases (all in high 
income countries) and 1.7% of outpatient cases (Supplementary Table 1). Studies from the USA and 
Canada accounted for 50.8% of the inpatient cases and 98.0% of the outpatient cases. Inpatient 
management in middle-income countries were mostly reported in studies from the Western Pacific 
Region (WPR). The weighted mean cost for inpatient management without follow-up was similar in 
EUR and WPR (€ 1,530 vs € 965), whereas the cost in the USA and Canada was nearly 4-6 times 
higher (€ 6,315). Inpatient management costs with follow-up in high income countries of EUR, AMR 
and WPR was € 18,607, € 9,506 and € 4,775 respectively. 
Direct and indirect non-medical costs were reported in 7 studies. Direct non-medical costs (mainly 
food and transportation) were reported to be 2.3-3.8% of the total management cost per patient. 
Indirect costs representing productivity losses were reported to be 5.8–31.6% of the total 
management cost (Table 2). 
Costs for special risk groups were compared with the costs for healthy full term infants. Children with 
comorbidities, such as CHD, CLD and BPD, had increased cost for RSV management at € 9,825 
(95%CI: 900 - 18,839), €10,879 (95%CI:1,858 - 19,900), € 5,516 (95%CI:2,111 - 8,921) respectively 
(Table 3). Preterm children cost € 4,695 (95%CI: 3,852 -5,537) more than term children. A single study 
in Malaysia reported higher costs for preterm infants and children with underlying disease: nearly 12 
times the cost for healthy full-term infants. (Supplementary Table 7). ICU care was € 14,809 (11,210 
- 18,409) more expensive than non-ICU care (Table 3).  
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Global cost estimates RSV management  
We estimated that the global direct medical costs for management of RSV-ALRI in children aged 
below 5 years in 2017 was about € 4.82 billion (95% CI: 3.47- 7.93) from the health care payer’s 
perspective, of which nearly 55% were hospitalization costs (€ 2.65 billion, 95% CI: 2.26 -3.28) and 
outpatient management accounted for the remainder (€2.17 billion, 95% CI: 1.20 -4.65) (Table 4) 
.This estimate includes the direct medical cost only. Direct non-medical costs and indirect costs 
would futher add 8.7% and 31.6%, respectively, to the total direct medical costs. The total cost in 
developing countries, where 92% of cases occured, was € 3.13 billion (95% CI: 2.27 -5.13) , 
accounting for 65% of the RSV economic burden globally and 2.7 ‰ (95%CI: 0.3‰ – 8.3‰) of the 
healthcare expenditure in these countries[48].  
Discussion 
This is the first systematic review and meta-analysis summarising the current evidence related to the 
cost of RSV disease among children below 5 years of age. It demonstrates that the economic burden 
associated with RSV disease is substantial. The estimated global costs of RSV-ALRI inpatient and 
outpatient management from a healthcare payer’s perspective was € 4.82 billion (95% CI: 3.47 -7.93) 
in children younger than 5 years in 2017. Relative to global healthcare expenditure, RSV management 
costs in children below 5 years old alone accounted for 0.7 ‰ (95% CI: 0.2‰ – 14.7‰) [48].  
 
This study demostrates the level of budget that could be avoided (and made available for other health 
service needs) if there were prophylactic strategy to prevent many of these episodes. Direct non-
medical and indirect costs may further contribute to the financial and social burden on families of 
children affected by RSV disease. Outpatient follow-up after initial RSV disease episodes may reveal 
additional costs compared to the analysis restricted to a single clinic visit, but outpatient care may 
also be effective in preventing additional cost due to re-hospitalization.  
The average cost of inpatient hospitalization per patient was highly dependent on the setting. The 
substantial differences in cost between settings may be due to the overall economic situation as well 
as different requirements/thresholds for hospitalization. Inpatient cost in middle-income countries was 
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even higher than the inpatient cost in high-income countries (1.53 billion vs. 1.15 billion). 
Hospitalization costs accounted for 55% of the all RSV management cost globally and 65% of the 
total RSV cost generated in developing countries. Meanwhile, the mean cost per inpatient for RSV 
management exceeded the total healthcare expenditure per capita in most OECD countries [7]. The 
above evidence indicates that RSV management places a heavy burden on the healthcare system, 
particularly in developing countries.   
The baseline risk status (eg. prematurity) should be documented, as the cost for high risk groups 
would potentially increase. Hospitalisation costs in children with risk factors (early and late pre-term, 
CHD and CLD) were substantially higher (1.8-5.9 times) compared to children without such risk 
factors. This reflects that patients with comorbidities, who, on average, experience more severe RSV 
infections, typically require prolonged hospital stays and/or ICU admission. It may also be affected by 
the accessibility to ambulatory and primary care.  
Very few studies investigated the indirect costs incurred by parents or families taking care of children 
with RSV infection. The need to take care of children with RSV may generate a significant additional 
burden (including financial) on parents and other caregivers. On the one hand, indirect costs may 
generate more costs to family and society. The indirect cost of RSV management accounted for 20% 
of the total cost in Bangladesh [46]. The productivity loss per case of RSV in the US was reported as 
US$2,697-5,439[27]. On the other hand, out-of-pocket payments for RSV management can cause 
households to incur catastrophic expenditures, which in turn can push them into poverty. The out-of-
pocket cost was 24% (range 17%-32%) of monthly household income of affected families in 
Bangladesh[46]. Without healthcare insurance, over 50% of the studied families obtained loans to 
meet treatment cost. This was also observed for child pneumonia management in other low-income 
countries, such as Ethiopia[49]. Coping with considerable costs of RSV management in middle and 
low income countries can lead to catastrophic consequences and impoverishment for the affected 
families. More cost studies are needed to better understand the impact and the possible benefits of 
adequate prevention.  
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RSV infection may lead to prolonged respiratory morbidity following an initial disease episode. Follow-
up studies provided insight into the financial burden generated by prolonged RSV disease. The 
inpatient costs per admission nearly doubled and the duration of hospital stays increased by 33% in 
the studies with follow-up. Consequently, reported outpatient costs also increased up to 12-fold 
compared to a single primary care or emergency room visit. Therefore, outpatient costs of managing 
RSV infection are likely to be substantial when costs are monitored beyond the acute period. Further 
studies are required to advance our understanding of the long-term costs and consequences of RSV 
disease.  
This study highlights the broad range of allied costs related to RSV-ALRI (at regional and country 
levels) due to differences in management styles, cost reporting methods, and access to care in 
different parts of the world. Regardless of the setting and methodological heterogeneity, our data 
underline the urgent need for effective means of disease prevention and intervention, i.e. the 
development of RSV vaccines and therapeutics. The differences in costs reported from different 
sources and the methodological standardization achieved in this current study provide a useful 
roadmap for future research, which is urgently needed considering the imminent development of new 
options for the treatment and prevention of RSV disease. 
 
Several limitations of this meta-analysis should be noted: First, only 14 publications (35%) specified 
the exact range of costs including mean and median costs, and no data sets were obtained from study 
authors except unpublished studies. Adequate representation of cost data should always include both 
a central estimate (ie mean and median) and an associated uncertainty interval (SD, 95% CI or 
interquartile range) Secondly, the methods for case ascertainment differed significantly from study to 
study ranging from suspected RSV diagnoses as they were coded in clinical records (ICD-9, ICD-10), 
to laboratory methods with highly variable sensitivity and specificity. RSV cases may be underreported 
by using ICD codes. Third, the USA is known to be an outlier in terms of health care costs per case, 
and therefore not representative for the Americas, or for any other group of countries. The fact that a 
disproportionately large number of US studies were found (18/41), introduces an upward bias in some 
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of our summary estimates. Fourth, our results should be interpreted with caution as there are 
limitations to using meta-analysis in the context of healthcare costs which have significant 
hetergeneity and are likely context and site specific.. Additionally, the true uncertianity in the results 
are likely to be much wider than the (narrow) 95%CI reported in our analyses. Finally, due to a lack 
of data in outpatient settings and in low income countries, the global cost estimate may be further 
overestimated. In our analysis, data from middle income countries were used as proxy for cost data 
for developing countries, which may have also contribute to the differences compared to our previous 
estimates for all-cause pneumonia [50]. This may be further magnified by our assumption of universal 
coverage of treatment in children with RSV-ALRI. Of note, these reported costs exceed previous 
estimates on the cost of child pneumonia management - €1.7 (95% CI: 0.6 – 2.8) billion (price year: 
2017) from the healthcare perspective [9]. 
 
This review provides a first overview of treatment costs related to of RSV disease in different parts of 
the world. There was an imbalance in geographical representation of the data collected, with no data 
from South America and Africa and very limited data from South East Asia and the Eastern 
Mediterranean regions of WHO. Despite this, our study provides a first set of important information 
on management costs for hospital administrators, public health stakeholders and policy makers, 
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Table 1 Meta-analysis results of weighted mean hospital LOS per patient and range of 
mean cost by WHO region and patient group (printed) 
WHO Region Patient Group Sample Size  
(% of global 
sample size) 
Weighted Mean 
LOS (Days) (95%CI) 
Range of Mean Cost 
Per Patient/Episode 
(Euro€ 2017)  
Global  Inpatient Overall 337,775 (100%) 3.51 (3.47- 3.55) 79-30,350 
      Inpatient without follow-up 244,913 (100%) 3.28 (3.23 -3.34) 79-30,350 
 High income countries 240,730 (100%) 3.09 (3.03-3.15) 781-30,350 
 Middle income countries 4,183 (100%) 6.41 (6.36-6.46) 79-577 
 Inpatient with follow-up 82,859 (100%) 4.2 (4.18-4.21) 419-28,608 
 Outpatient Overall 36,286 (100%) N/A 57-8,691 
 Outpatient without follow-up 21670 (100%) N/A 57-1,029 
 High income countries 21625 (100%) N/A 231-1,029 
 Middle income countries 45 (100%) N/A 57-304 
 Outpatient with follow-up 14,616 (100%) N/A 69-8,691 
EUR  
(10 studies) 
Inpatient Overall 136,311 (40.3%) 2.68 (2.63 -2.72) 781-25,612 
    Inpatient without follow-up* 136,261 (55.6%) 2.67 (2.62 -2.71) 781-6,156 
Inpatient with follow-up 50 (0.6%) 39.8 (33.7 -45.9)** 2,147-25,612 
Outpatient Overall 633 (1.7%) N/A 87-3,031 
Outpatient without follow-up 633（2.9%） N/A 87-292 
Outpatient with follow-up       － N/A 676-3,031 
AMR  
(19 studies)+ 
Inpatient Overall 170,891 (30.8%) 3.96 (3.89 -4.04) 419-30,350 
    Inpatient without follow-up* 104,201(42.5%)  3.64 (3.52 – 3.76) 3,022-30,350 
Inpatient with follow-up 66,690 (80.4%)  4.46 (4.44 -4.48) 419-28,608 
Outpatient Overall 35,575 (98.0%) N/A 69-8,691 
Outpatient without follow-up 20,959 (96.7%) N/A 117-1,029 
Outpatient with follow-up 14,616 (100%) N/A 69-8,691 
WPR 
(10 studies) 
Inpatient Overall 30,067 (4.1%) 4.6 (4.57-4.62) 215-4,921 
     Inpatient without follow-up 13,948 (5.6%)  6.43 (6.38-6.49) 215-1,817 
Inpatient with follow-up 16,119 (19.4%)  3.0 (2.99 – 3.01) 4,630-4,921 
Outpatient Overall 57 (0.2%) N/A 183-304 
Outpatient without follow-up 57(0.2%) N/A 183-304 
Outpatient with follow-up - N/A - 
SEAR 
(1 study) 
Inpatient without follow-up     
       (Middle income countries) 
39 (0.9%) 4.59 (4.57-4.62) 79-150 
 Outpatient Overall 21(0.1%)  57-106 
EMR 
(1 study) 
Inpatient without follow-up  
       (Middle income countries) 
467 (11.1%) 4.27 (4.24-4.30) 577 
* All high income countries only; N/A: Not Applicable; EUR: European Region, AMR: Region of The Americas, WPR: Western Pacific Region, 
SEAR: South East Asia Region; EMR: Eastern Mediterranean Region. **Based on one study only, with 2 years follow-up. + Based on 18 
US studies and 1 Canadian study.   
Table 2 Percentage of direct non-medical cost and indirect cost in total cost per episode 
(online) 






Direct non-medical cost Ehlken 2005[10] Germany 129(154) 3.80% 
    Leader 2003[27] USA 241(1,545) - 
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Miedema 2001[11] 











Indirect cost Ehlken 2005[10] Germany 198(366) 5.80% 
 Garcia-Marcos 
2014[14] 
Spain 47(61) 15.90% 
  Leader 2003[27] USA 2,307 – 4,652 - 
 Bhuiyan 2017[46] Bangladesh 31 [18-47] 20.21% 
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Table 3 Cost differences between high-risk group and low risk groups  (online) 
 
Risk Group WHO Region (Study country, 
number of studies) 
Weighted Cost Difference 
(95% CI) Euro 2017 
Low risk vs. High risk*  Overall  
EUR (Netherlands, UK, 2) 
AMR (USA,8) 
WPR (Australia, Taiwan China, 
Malaysia, 5) 
4,160 (3,237 - 5,082) 
2,274 (-1,152 - 5,702) 
9,661 (6,669 - 11,234) 
2,174 (1,266 - 3,075) 
Term children vs. preterm 
children  
Overall  
EUR (Netherlands, 1) 
AMR (USA, 9) 
WPR (Australia, Malaysia, 3) 
4,695 (3,852 - 5,537) 
3,364 (839 - 5,890) 
6,626 (5,175 - 8,077) 
3,240 (2,638 - 3,841) 
 
Normal vs. low birth weight 
(<2500g) 
Overall  
EUR (Netherlands, 1) 
WPR (Australia, 2) 
1,249 (757 - 1,740) 
1,320 (789 - 1,850) 
1,247 (113 - 2,383) 
Term vs. CHD Overall  
AMR (USA, 4) 
    WPR (Australia, 1) 
9,825 (900 - 18,839) 
12,807 (1,906 - 23,707) 
-775 (-2,352 - -802) 
Term vs. CLD Overall  
AMR (USA, 4) 
    WPR (Australia, 1) 
10,879 (1,858 - 19,900) 
12,571 (-2,298 - 27,441) 
4,127 (2,825 - 5,429) 
Term vs. BPD Overall  
EUR (Netherlands 1) 
    WPR (Australia, 1) 
5,516 (2,111 - 8,921) 
3,548 (1,118 - 5,978) 
7,049 (6,810 - 7,289) 
Non-ICU vs. ICU Overall  
AMR (USA, 2) 
EUR (Germany, 1) 
WPR (Australia, China, 
Malaysia, 3) 
14,809 (11,210 - 18,409) 
44,751 (5,437 - 84,067) 
17,750 (13,911 - 21,589) 
1,412 (167 - 2,658) 
LBW: Low birth weight; CHD: congenital heart disease; CLD: chronic lung disease; BPD: Bronchopulmonary dysplasia; ICU: 
intensive care unit.  * High risk including: preterm, CLD, CHD, LBW, BPD, vulnerable children, multiple underlying diseases, 
indication for prophylaxis.
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Table 4 Global cost estimates for RSV management (online) 
Patient Group 
RSV management costs 
in developed countries 
(Billion € (95% CI)) 
RSV management costs 
in developing countries 
(Billion € (95% CI)) 
Total Costs 
(Billion € (95% CI)) 
 
Inpatient 1.15 (0.97 – 1.46) 1.53  (1.29 – 1.82) 2.65 ( 2.26–  3.28) 
Outpatient 0.58 (0.23-1.33) 1.60 (0.97 – 3.31) 2.17 (1.20 – 4.65) 
Total 1.69 (1.20 – 2.79) 3.13 (2.27- 5.13) 4.82 (3.47 – 7.93) 
 
Figure 1. Overview of Search Results (Online) 
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Figure  2. Cost per episode for inpatient management by WHO region (online) 
Legend; EUR: European Region, AMR: Region of The Americas, WPR: Western Pacific Region, SEAR: South East 
Asia Region; EMR: Eastern Mediterranean Region. 
